Blood–Brain Barrier Disruption (BBBD)-Based Immunochemotherapy for Primary Central Nervous System Lymphoma (PCNSL), Early Results of a Phase II Study

SIMPLE SUMMARY: We present the results of a prospective trial of systemic chemoimmunotherapy for primary CNS lymphoma including the intra-arterial administration of methotrexate and carboplatin with blood–brain barrier disruption. The safety, response rates, and survival outcomes were favorable. Pre...

Descripción completa

Detalles Bibliográficos
Autores principales: Kuitunen, Hanne K., Rönkä, Aino L. K., Sonkajärvi, Eila M., Isokangas, Juha-Matti, Pyörälä, Marja, Palosaari, Kari A. A., Jokimäki, Anna S., Partanen, Anu E., Littow, Harri J., Vakkala, Merja A., Jantunen, Esa J., Huttunen, Mirja E., Marin, Katja J., Aromaa-Häyhä, Annikki M. K., Auvinen, Päivi K., Selander, Tuomas, Puhakka, Inka K., Kuittinen, Outi M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953868/
https://www.ncbi.nlm.nih.gov/pubmed/36831682
http://dx.doi.org/10.3390/cancers15041341

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953868/
https://www.ncbi.nlm.nih.gov/pubmed/36831682
http://dx.doi.org/10.3390/cancers15041341

Ejemplares similares